G-CSF induces CD15
CD15+CD14+
G‐CSF
MDSC
cancer
placenta
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
11
2021
revised:
21
03
2022
revised:
27
04
2022
accepted:
03
05
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Recombinant granulocyte colony-stimulating factor (G-CSF) is frequently administered to patients with cancer to enhance granulocyte recovery post-chemotherapy. Clinical trials have also used G-CSF to modulate myeloid cell function in pregnancy and inflammatory diseases. Although the contribution of G-CSF to expanding normal granulocytes is well known, the effect of this cytokine on the phenotype and function of immunosuppressive granulocytic cells remains unclear. Here, we investigate the impact of physiological and iatrogenic G-CSF on an as yet undescribed granulocyte phenotype and ensuing outcome on T cells in the settings of cancer and pregnancy. Granulocytes from patients treated with recombinant G-CSF, patients with late-stage cancer and women enrolled on a trial of recombinant G-CSF were phenotyped by flow cytometry. The ability and mechanism of polarised granulocytes to suppress T-cell proliferation were assessed by cell proliferation assays, flow cytometry and ELISA. We observed that G-CSF leads to a significant upregulation of CD14 expression on CD15 G-CSF induces a population of ROS
Identifiants
pubmed: 35602884
doi: 10.1002/cti2.1395
pii: CTI21395
pmc: PMC9114661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1395Informations de copyright
© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Science. 2016 Jun 3;352(6290):1232-6
pubmed: 27103670
Clin Cancer Res. 2018 Jun 15;24(12):2859-2872
pubmed: 29602801
J Immunotoxicol. 2016 Nov;13(6):784-792
pubmed: 27417188
Am J Reprod Immunol. 2015 Jun;73(6):479-86
pubmed: 25496212
J Immunol. 2017 Nov 15;199(10):3406-3417
pubmed: 28986438
Science. 1990 Sep 21;249(4975):1431-3
pubmed: 1698311
Front Cell Dev Biol. 2020 Dec 22;8:601043
pubmed: 33415106
Blood. 2010 Oct 7;116(14):2462-71
pubmed: 20581311
Eur J Immunol. 2014 Sep;44(9):2582-91
pubmed: 24894988
Clin Sci (Lond). 2014 Mar;126(5):347-54
pubmed: 23962040
J Leukoc Biol. 2016 Sep;100(3):499-511
pubmed: 27203698
Nat Immunol. 2018 Jan;19(1):85-97
pubmed: 29167569
J Clin Oncol. 2002 Feb 1;20(3):727-31
pubmed: 11821454
Lancet Oncol. 2018 Dec;19(12):1617-1629
pubmed: 30442501
Blood. 2001 Apr 15;97(8):2514-21
pubmed: 11290617
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33737338
Cancer Immunol Immunother. 2022 Jul;71(7):1583-1596
pubmed: 34727230
Sci Transl Med. 2015 Apr 1;7(281):281ra42
pubmed: 25834108
JAMA Intern Med. 2021 Jan 1;181(1):71-78
pubmed: 32910179
Immunity. 2017 Oct 17;47(4):789-802.e9
pubmed: 29045907
Bone Marrow Transplant. 2020 Dec;55(12):2347-2349
pubmed: 32719501
J Clin Oncol. 2020 Jul 1;38(19):2160-2169
pubmed: 32343642
Cancer Res. 2010 Jan 1;70(1):68-77
pubmed: 20028852
Nat Med. 2018 Feb;24(2):224-231
pubmed: 29334374
Cancer Res. 2009 Feb 15;69(4):1553-60
pubmed: 19201693
Pediatr Blood Cancer. 2020 Oct;67(10):e28417
pubmed: 32729196
Cancer Discov. 2021 Nov;11(11):2693-2706
pubmed: 34635571
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Hum Reprod. 2019 Mar 1;34(3):424-432
pubmed: 30776296
Am J Hematol. 2015 Jan;90(1):E9-E16
pubmed: 25303038